Intellia Therapeutics Inc investor relations material

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's therapies are based on a targeted genome editing platform, including CRISPR/Cas9 and proprietary next-generation programmable nucleases (PNs), which can induce a range of large deletions, substitutions or insertions across a target gene. The CRISPR/Cas9 genome editing technology has been shown to be effective in editing genomes in multiple cell types and organisms. Intellia Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.